• Cyclopamine, APOC1, and Papillary Thyroid Cancer

  2026-10-16

  Wang et al. investigated APOC1 as a prognostic and functional factor in papillary thyroid carcinoma (PTC) and used Connectivity Map analysis to nominate Cyclopamine as a candidate compound. Their evidence linked elevated APOC1 with aggressive clinicopathological features, apoptosis resistance, and immune-evasion signatures, while Cyclopamine reduced PTC cell growth and suppressed tumors in a mouse model. The study supports a biologically plausible APOC1-associated vulnerability, but it does not yet establish direct APOC1 binding, definitive Hedgehog-pathway mediation, or clinical efficacy.

• Estradiol Benzoate: Evidence and Scope

  2026-10-16

  A source-grounded overview of Estradiol Benzoate as a cataloged synthetic estradiol analog and reported estrogen receptor alpha agonist. The available product information describes ERα binding across human, murine, and chicken contexts, but does not provide an identity-matched research paper, assay design, independent replication, or downstream signaling outcomes.

• L-Phenylephrine: Evidence, Mechanism, and Scope

  2026-10-15

  A source-limited appraisal of L-Phenylephrine as an adrenergic α1A receptor agonist, distinguishing supplier-documented identity and biological claims from independently verified research evidence.

• Exemestane: Mechanism, Evidence, and Scope

  2026-10-15

  Exemestane is described by APExBIO as a steroidal aromatase inhibitor that irreversibly inactivates aromatase and thereby reduces estrogen biosynthesis. The cited product information reports biochemical potency values and activity across several model types, but does not provide an identity-matched paper, assay details, effect sizes, sample sizes, comparators, or uncertainty estimates needed for independent evaluation.

• Murine RNase Inhibitor: Evidence and Scope

  2026-10-14

  The APExBIO product description identifies Murine RNase Inhibitor as a 50 kDa recombinant mouse protein intended to bind selected pancreatic-type RNases. Its reported specificity and oxidation-resistance rationale are product claims, not findings from an identity-matched research study. The available evidence supports a bounded mechanism overview, but not conclusions about comparative performance, assay outcomes, clinical use, or broad RNA protection.

• What MnTBAP Shows—and Does Not—in Stress Models

  2026-10-14

  A 2025 rat study connects chronic stress with depression-like behavior, brain mitochondrial dysfunction, and inflammatory signaling, while reporting behavioral improvement after a central MnTBAP intervention. The findings support mitochondrial redox imbalance as a contributor, but they do not establish a single causal pathway or demonstrate clinical relevance.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-10-13

  A 2024 bioRxiv preprint identifies CLCC1 as a host factor associated with the membrane-fusion stage of herpes simplex virus 1 nuclear egress. The findings connect CLCC1 loss with impaired capsid release, perinuclear vesicle accumulation, reduced viral output, and defects in nuclear pore complex insertion. Because the report was not peer reviewed and the supplied summary does not establish a direct molecular fusion mechanism, its conclusions remain provisional. The study also provides no evidence linking Spermine or endogenous polyamine biology to CLCC1.

• Alkaline Phosphatase Kit: Evidence Scope

  2026-10-13

  The Alkaline Phosphatase (AP) Substrate Test Kit, SKU K4151, is documented as a BCIP/NBT chromogenic reagent system for visualizing alkaline phosphatase enzyme activity. Available information supports its identity and conceptual purpose, but not application-specific performance or independent validation.

• AMPK, Mitophagy, and Periodontal Inflammation

  2026-10-12

  A 2026 FASEB Journal study links AMPK-regulated mitophagy with inflammatory responses to mechanical loading in periodontal ligament fibroblasts under diabetic-like conditions. The findings support a mechanistic association, but they do not establish a clinical treatment or show that AICAR phosphate was used. Product-level claims about Acadesine in B-cell chronic lymphocytic leukemia represent a separate evidence context.

• Elobixibat Hydrate: What the Evidence Shows

  2026-10-12

  Elobixibat hydrate is described by APExBIO as an ileal bile acid transporter inhibitor, but the supplied peer-reviewed study examines a different pathway: bradykinin B2-receptor modulation of peristalsis in isolated guinea pig ileum. That study offers context for gastrointestinal motility biology, not direct evidence of elobixibat’s efficacy, safety, or clinical use.

• ALC-0315: Identity and Evidence Boundaries

  2026-10-11

  ALC-0315 is documented by APExBIO as an ionizable amino lipid intended as a component of lipid nanoparticles for nucleic acid drug delivery. The available product information identifies its chemical composition and stated conceptual role, but no matched research paper was supplied to establish delivery performance, mechanism, safety, or clinical applicability.

• Angiotensin 1/2 (5-7): Evidence and Research Context

  2026-10-10

  A source-grounded overview of Angiotensin 1/2 (5-7), covering its identity within the renin–angiotensin system, reported spike–receptor binding findings, potential research questions, evidence strength, and key limitations.

• Toremifene in Breast Cancer: 20 Years of Evidence

  2026-10-09

  The reference paper synthesizes two decades of clinical and pharmacologic evidence for toremifene, positioning it as an effective endocrine option for selected postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is not a new trial, but an integrated interpretation of efficacy, safety, metabolism, biomarker-informed treatment, and the distinctions between selective estrogen receptor modulation and aromatase inhibition.

• Exemestane: Steroidal Aromatase Inhibitor

  2026-10-09

  Exemestane is a steroidal aromatase inhibitor that suppresses estrogen biosynthesis by inactivating cytochrome P450 aromatase. Vendor-reported biochemical benchmarks support its use as a mechanistic research tool, but assay-specific activity does not by itself establish clinical efficacy or performance in every breast cancer model.

• WZ4003 Lowers p-Tau Ser356 in Brain Slice Models

  2026-10-08

  A 2024 Acta Neuropathologica study connected tau phosphorylation at Ser356 with Alzheimer’s disease pathology and examined how the NUAK1/2 inhibitor WZ4003 affects this signal in mouse and human brain slice cultures. The findings support NUAK1-linked tau biology while also showing that treatment responses differ substantially between postnatal mouse tissue and adult human brain tissue.

7999 records 1/534 page Next 12345 下5页 Last page